View Profile

MARTHA SAHYLÍ ORTEGA PIJEIRA

Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals/ Nuclear Engineering Institute · Brazilian Nuclear Energy Commission

https://researchid.co/msopijeira
@gov.br
257Google Scholar Citations
8Google Scholar h-index
6Google Scholar i10-index

Research Interests

Radiochemistry, radiopharmacy, nanomedicine, PET imaging, targeted radionuclide therapy, radiotheranostic

Biography

Martha Sahylí Ortega Pijeira holds a B.Sc. in Radiochemistry (2012) and a MSc. in Radiochemistry (2015) from the Higher Institute of Technologies and Applied Sciences (InSTEC, Cuba), and a Ph.D. in Nuclear Technology from the Nuclear and Energy Research Institute (IPEN/CNEN-SP) and the University of São Paulo, Brazil (2019). She was a Visiting International Research Student (VIRS) at the University of British Columbia, Canada (2016-2017). She completed a post-doc in Radiopharmacy at IPEN/CNEN-SP (2021). Her working experience comprises the fields of radiochemistry, radiopharmacy, organic chemistry, nanomedicine, and applications of radiotracers in industry and the environment. She is currently doing a post-doc at the Laboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals from the Nuclear Engineering Institute (IEN/CNEN-RJ), Brazil.

Education

B.Sc. in Radiochemistry (2007-2012) from the Higher Institute of Technologies and Applied Sciences (InSTEC), Cuba. Field: Radiotracers for industry; M.Sc. in Radiochemistry (2012-2015) from the Higher Institute of Technologies and Applied Sciences (InSTEC), Cuba. Field: Radiotracers for industry; Ph.D. in Nuclear Technology (2015-2019) from the Nuclear and Energy Research Institute (IPEN/CNEN-SP), São Paulo, Brazil. Field: Radiopharmacy.

Recent Google Scholar Publications

  1. Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma
    ACS Pharmacology & Translational Science 8 (11), 3886-3895 , 2025, 2025
  2. Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future
    Current Medicinal Chemistry 31 (34), 5481-5534 , 2024, 2024 | Citations: 2.0
  3. Micellar solution of [223Ra] RaCl2: Reaching renal excretion, potent efficacy in osteoblastic osteosarcoma in PDX model, biochemistry alterations and pharmacokinetics
    International Journal of Pharmaceutics 652, 123765 , 2024, 2024 | Citations: 2.0
  4. Efficacy Of [223Ra] Racl2 In Nanomicellar Form: Targeting Renal Pathways, Osteosarcoma Therapy In PDX Models, And Pharmacokinetic-Biochemical Analysis
    Proceedings of the INAC 2024: international nuclear atlantic conference … , 2024, 2024
  5. The impact of radiolabeled nanomaterials
    Current Radiopharmaceuticals 16 (4), 337-339 , 2023, 2023 | Citations: 2.0

Links